Pfizer Net Long-Term Debt 2010-2025 | PFE
Pfizer annual/quarterly net long-term debt history and growth rate from 2010 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Pfizer net long-term debt for the quarter ending March 31, 2025 was $0M, a 100% decline year-over-year.
- Pfizer net long-term debt for the twelve months ending March 31, 2025 was $-6.750B, a 107.96% decline year-over-year.
- Pfizer annual net long-term debt for 2024 was $-2.25B, a 107.96% decline from 2023.
- Pfizer annual net long-term debt for 2023 was $28.262B, a 956.94% decline from 2022.
- Pfizer annual net long-term debt for 2022 was $-3.298B, a 227.51% increase from 2021.
Pfizer Annual Net Long-Term Debt
(Millions of US $) |
| 2024 |
$-2,250 |
| 2023 |
$28,262 |
| 2022 |
$-3,298 |
| 2021 |
$-1,007 |
| 2020 |
$1,219 |
| 2019 |
$-1,864 |
| 2018 |
$1,408 |
| 2017 |
$-880 |
| 2016 |
$3,287 |
| 2015 |
$-2,990 |
| 2014 |
$2,381 |
| 2013 |
$2,472 |
| 2012 |
$-1,513 |
| 2011 |
$-6,986 |
| 2010 |
$-6 |
| 2009 |
$23,056 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$132.981B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
